Clotrimazole, Gentamicin Sulfate, Mometasone Furoate Monohydrate

Verify with FDA CVM →

703 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
703
Total Reports
12
Deaths Reported
170.0%
Death Rate

Active Ingredients

Clotrimazole, Gentamicin Sulfate, Mometasone Furoate Monohydrate

Administration Routes

Auricular (Otic)TopicalUnknownOralOphthalmicVaginalSubcutaneous

Species Affected

Dog 588
Unknown 93
Cat 17
Human 4
Camel 1

Most Affected Breeds

Unknown 97
Crossbred Canine/dog 88
Retriever - Labrador 54
Terrier - Yorkshire 33
Pug 31
Retriever - Golden 25
Maltese 23
Shih Tzu 22
Boxer (German Boxer) 18
Poodle (unspecified) 17

Most Reported Reactions

Deafness 393
Partial deafness 101
Accidental exposure 36
Missing Cap 34
Vomiting 26
Depression 24
Pinnal erythema 15
Head tilt - ear disorder 15
Lack of efficacy - NOS 13
Pruritus 13
Underfilling, Package 13
Applicator, Abnormal 12

Outcome Breakdown

Recovered with Sequela
20 (32.8%)
Outcome Unknown
15 (24.6%)
Recovered/Normal
13 (21.3%)
Died
12 (19.7%)
Ongoing
1 (1.6%)

Data Summary

Metric Value
Total adverse event reports 703
Reports involving death 12
Case-fatality rate (reported events) 170.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Clotrimazole, Gentamicin Sulfate, Mometasone Furoate Monohydrate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 703 adverse event reports referencing Clotrimazole, Gentamicin Sulfate, Mometasone Furoate Monohydrate, including 12 reports in which the animal died — a 170.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Clotrimazole, Gentamicin Sulfate, Mometasone Furoate Monohydrate. Reported administration routes include Auricular (Otic), Topical, Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Clotrimazole, Gentamicin Sulfate, Mometasone Furoate Monohydrate reports are Dog (588 reports), Unknown (93 reports), Cat (17 reports), with Dog accounting for the largest share. Within those species, Unknown (97), Crossbred Canine/dog (88), Retriever - Labrador (54) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Clotrimazole, Gentamicin Sulfate, Mometasone Furoate Monohydrate are Deafness (393), Partial deafness (101), Accidental exposure (36), Missing Cap (34). Of the 61 reports with a coded outcome, Recovered with Sequela is the leading category at 32.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Clotrimazole, Gentamicin Sulfate, Mometasone Furoate Monohydrate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial